硬化疗法联合鼻腔局部普萘洛尔治疗:遗传性出血性毛细血管扩张症相关鼻出血的有效且安全疗法
该观察性横断面研究评估了硬化疗法联合0.5%普萘洛尔鼻腔制剂对遗传性出血性毛细血管扩张症(HHT)所致鼻出血的疗效。38例连续患者接受联合治疗,平均治疗37.1周后,鼻出血严重度评分(ESS)从6.9±2.6降至1.9±1.3(P<0.05),生活质量EQ-5D和VAS评分均显著提高(P<0.05)。结论认为联合治疗可显著减少HHT鼻出血并提高生活质量。
要点
- 硬化疗法联合0.5%普萘洛尔鼻腔局部治疗可显著降低HHT患者鼻出血频率和严重度。
- 治疗后ESS从6.9±2.6降至1.9±1.3,EQ-5D从0.66±0.27升至0.93±0.12(P<0.05)。
- VAS评分从44.6±28.3升至82.5±12.5(P<0.05),生活质量改善与ESS下降一致。
核心结论
- 研究证明硬化疗法联合鼻腔局部普萘洛尔治疗可显著减少HHT所致鼻出血并提高患者生活质量。
研究设计与样本
- 观察性横断面研究,纳入38例连续接受联合治疗的患者,平均年龄57.2岁(标准差13.9),女性占60.5%。
主要发现
- 平均治疗时间37.1周(标准差14.9)。
- ESS从基线6.9±2.6降至1.9±1.3,改善5分(P<0.05)。
- EQ-5D评分从0.66±0.27升至0.93±0.12(P<0.05)。
- VAS均值从44.6±28.3升至82.5±12.5(P<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Epistaxis is the most frequent clinical manifestation of hereditary hemorrhagic telangiectasia (HHT). Several topical, systemic, and surgical treatments have been tried, but none have been completely effective. The aim of the present study is to evaluate whether a combined treatment sclerotherapy and topical therapy with propranolol 0.5% nasal formulation would reduce the epistaxis due to HHT and improve patient's quality of life. METHODS: An observational cross-sectional study was carried out. The primary outcome measure was frequency and severity of epistaxis as measured by the epistaxis severity score (ESS) at baseline (4 weeks before therapy) and at least 4 weeks after the treatment was implemented. Quality of life was analyzed using EuroQol-5D (EQ-5D) scale and visual analogue (VAS) scale before and after treatment. RESULTS: A total of 38 consecutive patients subjected to the combined treatment were evaluated (mean age: 57.2 years, standard deviation [SD] = 13.9; 60.5% women). The mean time of treatment was 37.1 weeks (SD = 14.9). Combined therapy significantly reduces frequency and severity of epistaxis, with an ESS improvement of 5 points from 6.9 ± 2.6 to 1.9 ± 1.3 (P < 0.05); however, the EQ-5D scale increased from 0.66 ± 0.27 to 0.93 ± 0.12 (P < 0.05). The difference in VAS means showed an increase from 44.6 ± 28.3 to 82.5 ± 12.5 (P < 0.05). The increases in quality of life are in line with the drop in ESS. CONCLUSION: The study demonstrated that combined therapy (sclerotherapy and topical nasal propranolol) significantly reduced the epistaxis due to HHT and increased patients' quality of life. LEVEL OF EVIDENCE: 2c Laryngoscope, 129:2216-2223, 2019.
引用
- Esteban-Casado S, Martín de Rosales Cabrera AM, Usarralde Pérez A, et al. Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis. Laryngoscope. 2019. PMID: 30908653. doi:10.1002/lary.27930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。